Shattuck Labs Announces Participation in Upcoming May Conferences

AUSTIN, TX and DURHAM, NC, April 30, 2021 (GLOBE NEWSWIRE) — Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that Taylor Schreiber, M.D., Ph.D., Shattuck’s Chief Executive Officer, will participate in two upcoming conferences. Presentation DetailsConference: 32nd Annual Cello Health Cancer Progress ConferenceTitle: Multifunctional Soluble Biologics: Binders, Binders Everywhere Format: Panel discussionDate: May 5, 2021Time: 11:45 a.m. EST Conference: 17th Annual PEGS Boston ConferenceTitle: Ranking Product Attributes to Select an Appropriate Expression PlatformFormat: Panel discussionDate: May 11, 2021Time: 12:20 p.m. EST The presentations and panel discussions will be available to registered conference attendees. About Shattuck Labs, Inc.Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck’s proprietary Agonist Redirected Checkpoint, ARC®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company’s lead wholly owned program, SL-172154 (SIRPα-Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in a Phase 1 trial. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with Takeda Pharmaceuticals. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com. Investor Contact: Conor RichardsonSenior Director, Finance & Investor RelationsShattuck Labs, [email protected] Media Contact:Stephanie Ascher Managing DirectorStern Investor Relations, [email protected]